Zynex Files For Bankruptcy, Faces Class Action Over Fraud Allegations

Edgen Stock·Mar 21 2026, 20:05

Share to

Share to

Copy link

Key Takeaways

A securities class action lawsuit has been filed against medical device company Zynex, Inc. after it filed for Chapter 11 bankruptcy and was delisted. The legal action follows revelations of a massive overbilling scheme that triggered the company's collapse, leading to a near-total loss for investors.

A securities class action lawsuit was filed against Zynex, Inc. and its former executives following the company's Chapter 11 bankruptcy.
The company's collapse was driven by allegations of a massive overbilling scheme, which led to its stock being delisted.
Announced on March 21, 2026, the developments signify a catastrophic loss for shareholders, wiping out nearly all investment value.

Zynex Files for Chapter 11, Triggering March 21 Lawsuit

On March 21, 2026, national law firm Hagens Berman announced it had filed a securities class action lawsuit against Zynex, Inc. (trading under ZYXI / ZYXIQ) and its former senior leadership. The legal action directly follows the company’s Chapter 11 bankruptcy filing and subsequent delisting from public exchanges. These drastic measures were taken after evidence of a significant fraudulent billing operation came to light, precipitating the company's financial implosion and prompting legal recourse for aggrieved investors.

Overbilling Scheme Allegations Erase Shareholder Value

The core of the lawsuit centers on allegations of a massive overbilling scheme that fundamentally misrepresented Zynex's financial health. For investors in Zynex, the bankruptcy and fraud allegations represent a catastrophic financial event, with the value of their holdings likely reduced to zero. The case is expected to have severe legal and financial consequences for the company's former executives. Furthermore, the high-profile failure could attract increased regulatory scrutiny to the broader medical billing and device sector, as authorities probe for similar fraudulent practices.